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To the Editor:
The recent review by Waters and Nelson
‘Are all nonthymidine analogue back-
bones appropriate for treating antiretro-
viral-naı ¨ve patients?’ (1) statesincorrectly
that the rates of hypersensitivity (HSR)
in the Zodiac Study were significantly
higher with abacavir (ABC) once daily
than with ABC twice daily (8 vs. 5%,
p < 0.02). In fact, the rates of suspected
ABC HSR in the Zodiac Study were 9%
(95% CI ¼ 6.6–12.7%) in the once-
daily treatment group and 7% (95%
CI ¼ 4.9–10.3%) with the twice-daily
regimen (2). In this double-blind,
placebo-matched study, there was no
significant difference in the clinical
presentation and/or frequency of HSR-
associated signs and symptoms reported
between the ABC once-daily and the
ABC twice-daily arms. Moreover, the
rates of HSR reported in this study
were consistent with those in other stu-
dies where the symptoms of HSR were
solicited using a specific, detailed report-
ing module (3). Analysis of safety para-
meters, including HSR, indicated no
increased risk with ABC once-daily
administration, compared with twice-
daily administration (2).
James and Johan-Ling refer to a
poster by James et al. and they are
correct that the overall HSR incidence
reported in nine recent clinical trials
using twice-daily ABC is 8% (4). By
contrast, however, an analysis reported
by Brothers et al. at the same confer-
ence, involving data from more than
9000 patients in 37 clinical trials,
shows an overall rate of suspected
hypersensitivity of 5.4% (5). Although
the result of the unplanned Fisher’s
exact test reported by James et al. in
Zodiac, comparing the frequency of
grade 3/4 suspected HSRs in the ABC
once-daily vs. the ABC twice-daily arms,
is p ¼ 0.02 (5 vs. 2%), it is important to
note that the exact confidence intervals
around each of these proportions overlap
(95% CI ¼ 3.0–7.6% and 0.7–3.7%).
The interpretation of this unplanned
statistical test should be made with
caution.Infact,nosignificantdifferences
in grade 3/4 HSRs, hospitalisations or
deaths attributed to HSR were seen in
the ABC once-daily vs. twice-daily arms
of six large studies (6), consistent with
the lack of a biological rationale for a
higher rate or severity of HSR when
ABC is given as 600 mg once daily vs.
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